MetaCap

Milestone Pharmaceuticals (MIST) vs Tonix Pharmaceuticals (TNXP)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Milestone Pharmaceuticals (MIST) has outperformed Tonix Pharmaceuticals (TNXP) over the past year, losing 84.5% versus a loss of 85.2%. Over five years, MIST leads with a -93.8% price change compared with -100.0% for TNXP. Tonix Pharmaceuticals is the larger company by market cap ($46.2 million vs $46.2 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

MIST-84.54%TNXP-85.22%
+29%-31%-91%
Nov 21, 20251 yearNov 20, 2026
MIST-93.88%TNXP-100.00%
+65%-22%-108%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

MIST versus TNXP key metrics
MetricMISTTNXP
Share price$0.3711$2.38
Market cap$46.20M$46.25M
1-day change-7.06%-6.67%
YTD return-81.63%-84.76%
1-year return-84.54%-85.22%
5-year return-93.85%-100.00%
EPS (TTM)$-0.74$-12.39
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$13.11M
Revenue growth (YoY)—+29.85%
Net income (latest FY)$-63.06M$-124.02M
Gross margin—49.34%
Operating margin—-959.05%
Net margin—-946.22%
52-week high$3.06$20.56
52-week low$0.362$2.30
Distance from 52-week high-87.87%-88.42%
Analyst consensusnonestrong_buy
Avg. price target upside+1479.09%+1769.75%
Average volume1.53M838.83K
Shares outstanding124.50M19.43M
Employees38142
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Milestone Pharmaceuticals

MIST stock →

Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines in the United States and Canada. It offers CARDAMYST (etripamil) nasal spray, a prescription medication for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults.

Health Care · Biotechnology: Pharmaceutical Preparations · 38 employees

About Tonix Pharmaceuticals

TNXP stock →

Tonix Pharmaceuticals Holding Corp., a fully integrated biopharmaceutical company, develops and commercializes therapies for central nervous system (CNS) disorders, immunology and immuno-oncology, infectious diseases, and rare diseases in the United States. The company offers TONMYA, a cyclobenzaprine HCl sublingual tablet for the treatment of fibromyalgia.

Health Care · Biotechnology: Pharmaceutical Preparations · 142 employees

MIST vs TNXP FAQ

Which is bigger, Milestone Pharmaceuticals or Tonix Pharmaceuticals?

Tonix Pharmaceuticals (TNXP) is larger, with a market capitalization of $46.25M compared with $46.20M for Milestone Pharmaceuticals (MIST).

Which stock has performed better over the past year, MIST or TNXP?

MIST returned -84.54% over the past 12 months, compared with -85.22% for TNXP (price return, excluding dividends). Past performance does not predict future results.

Are Milestone Pharmaceuticals and Tonix Pharmaceuticals in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons